October 10, 2020 : Issue #1070

SPECIAL FEATURE: AI & the Future of Diabetes Management

Collaborative Analysis Concludes that AI Tool Improves Outcomes

• Innovative Artificial Intelligence (AI) Tool Optimizes Care for T2D Patients, Part 2

TOP STORIES — Diabetes News and Research

Once-A-Week Insulin Will Happen

Amputations are No Longer Listed As a Box Warning For Canagliflozin

When Steve and I first started Diabetes in Control we tried to attend every conference and speak to every thought leader we could find. Back then pharmacists did not garner a lot of respect from endocrinologists, and often we were blown off for every interview. There were a few who were willing to take time with us, and one of those was Julio Rosenstock from the Dallas Diabetes Research Center. He was always on the cutting edge of diabetes research and would always take time to talk to us.

Because of this I am always happy to share his research with you, our readers.

This week our intern, Alexandria Bartley, PharmD. Candidate, FAMU College of Pharmacy, reviewed his research on a once-a-week insulin. As I sat there reading her article, I thought, wouldn’t it be great if a patient could take  1 injection of insulin icodec and 1 injection of a weekly GLP-1 mimic and be done for the week.

Note: Don’t miss part 2 of our special feature on “The Future of Type 2 Diabetes Management and The Changing Roles of Healthcare Professionals,” presented in three parts. The series is about how a team of physicians and pharmacists at St. Elizabeth Healthcare in Kentucky uses artificial intelligence to improve treatment, adherence, and cost savings for both Medicaid and Americans, and to get the patient to goal in a shorter period.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

See article 2.

Collaborative Analysis Concludes that the AI Tool Improves Outcomes for Type 2 Diabetes Patients 

A new clinical software using artificial intelligence is being used for those with Type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs. This feature is a 3-part series. 

The project was designed to address through clinical intervention the issues experienced by patients with diabetes, such as high A1c levels. Through team-based care, clinical software support, and patient engagement, the intervention was projected to help control HbA1c and potentially lower treatment costs.  

The end to every day insulin use may be in sight. 

The risk for leg and foot amputation is now listed under Warnings and Precautions instead of box warning. 

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Alexandria Bartley, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Tarshay Boyd, PharmD. Candidate, LECOM School of Pharmacy

Destiny Funchess, PharmD Candidate, Tougaloo College, South College School of Pharmacy

Chardae Whitner PharmD Candidate L|E|C|O|M Bradenton School of Pharmacy

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com